Show simple item record

FieldValueLanguage
dc.contributor.authorJansen, Jesse
dc.contributor.authorMcKinn, Shannon
dc.contributor.authorBonner, Carissa
dc.contributor.authorIrwig, Les
dc.contributor.authorDoust, Jenny
dc.contributor.authorGlasziou, Paul
dc.contributor.authorNickel, Brooke
dc.contributor.authorvan Munster, Barbara
dc.contributor.authorMcCaffery, Kirsten
dc.date.accessioned2017-02-20
dc.date.available2017-02-20
dc.date.issued2015-08-20
dc.identifier.citationJansen J, McKinn S, Bonner C, Irwig L, Doust J, Glasziou P, Nickel B, van Munster B, McCaffery K: Systematic review of clinical practice guidelines recommendations about primary cardiovascular disease prevention for older adults. BMC Fam Pract 2015, 16:104en
dc.identifier.urihttp://bmcfampract.biomedcentral.com/articles/10.1186/s12875-015-0310-1
dc.identifier.urihttp://hdl.handle.net/2123/16381
dc.description.abstractBackground: Clinical care for older adults is complex and represents a growing problem. They are a diverse patient group with varying needs, frequent presence of multiple comorbidities, and are more susceptible to treatment harms. Thus Clinical Practice Guidelines (CPGs) need to carefully consider older adults in order to guide clinicians. We reviewed CPG recommendations for primary cardiovascular disease (CVD) prevention and examined the extent to which CPGs address issues important for older people identified in the literature. Methods: We searched: 1) two systematic reviews on CPGs for CVD prevention and 2) the National CPG Clearinghouse, G-I-N International CPG Library and Trip databases for CPGs for CVD prevention, hypertension and cholesterol. We conducted our search between April and December 2013. We excluded CPGs for diabetes, chronic kidney disease, HIV, lifestyle, general screening/prevention, and pregnant or pediatric populations. Three authors independently screened citations for inclusion and extracted data. The primary outcomes were presence and extent of recommendations for older people including discussion of: (1) available evidence, (2) barriers to implementation of the CPG, and (3) tailoring management for this group. Results: We found 47 eligible CPGs. There was no mention of older people in 4 (9 %) of the CPGs. Benefits were discussed more frequently than harms. Twenty-three CPGs (49 %) discussed evidence about potential benefits and 18 (38 %) discussed potential harms of CVD prevention in older people. Most CPGs addressed one or more barriers to implementation, often as a short statement. Although 27 CPGs (58 %) mentioned tailoring management to the older patient context (e.g. comorbidities), concrete guidance was rare. Conclusion: Although most CVD prevention CPGs mention the older population to some extent, the information provided is vague and very limited. Older adults represent a growing proportion of the population. Guideline developers must ensure they consider older patients’ needs and provide appropriate advice to clinicians in order to support high quality care for this group. CPGs should at a minimum address the available evidence about CVD prevention for older people, and acknowledge the importance of patient involvement.en
dc.description.sponsorshipNHMRCen
dc.language.isoen_AUen
dc.publisherBioMed Centralen
dc.relationNHMRC 633003, NHMRC 511217, NHMRC 1037028, NHMRC 1029241,en
dc.rightsOther
dc.subjectAgeingen
dc.subjectCardiovascular diseasesen
dc.subjectGuidelinesen
dc.subjectShared decision makingen
dc.titleSystematic review of clinical practice guidelines recommendations about primary cardiovascular disease prevention for older adultsen
dc.typeArticleen
dc.subject.asrcFoR::111799 - Public Health and Health Services not elsewhere classifieden
dc.identifier.doi10.1186/s12875-015-0310-1
dc.type.pubtypePublisher's versionen
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.